May 19, 2023 / 10:00PM GMT
Operator
Thank you for standing by, and welcome to the Krystal Biotech VYJUVEK FDA Approval Conference Call. As a reminder, today's call is being recorded. I would now like to hand the conference over to your host, Meg Dodge, Head of Investor Relations and Corporate Communications. Please begin.
Meg Dodge - Krystal Biotech, Inc. - VP of IR & Corporate Communications
Hello, and thank you for joining us today to discuss the FDA approval of VYJUVEK as the first and only treatment in the U.S. for Dystrophic Epidermolysis Bullosa or DEB. With me on the call are Chairman and CEO, Krish Krishnan; Co-Founder and President of Research and Development, Suma Krishnan; Chief Commercial Officer, Andrew Orth; and Kate Romano, Chief Accounting Officer.
As we begin, I would like to point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings
Krystal Biotech Inc FDA Approval Call Transcript
May 20, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers